420 with CNW — Study Finds Frequent Cannabis Use Doesn’t Cause Paranoia, Lower Motivation

Recent research on the effects of regular marijuana usage disproves popular perceptions about the drug by showing no connection between habitual users’ decreased motivation or paranoia. The study found no indication of a marijuana-induced hangover the following day.

One of the unexpected results was that long-term users did not exhibit a decline in desire or effort-exertion willingness, either due to internal or external factors. In fact, consumers who used the product more frequently claimed to be more motivated and to have experienced more negative emotions and impulsivity.

The study highlights both expected and unexpected results, challenging misconceptions surrounding cannabis’ effects. The researchers attribute much of the misunderstanding to cannabis’ historical criminalization, which has skewed perceptions of the drug and its users. According to the authors, even though cannabis is widely used, especially when compared to tobacco, alcohol and caffeine, little is known about how it affects regular users in daily life.

Reddit served as a source for the study’s participants, who had to be at least 21 years of age and from Canada or the United States. Participants were required to use cannabis at least three times weekly for recreational purposes. Throughout the weeklong study period, participants completed a 30-minute baseline assessment and a brief assessment five times daily between 10 a.m. and 11 p.m.

The study found negligible influence on motivation, defying popular belief. Interestingly, the study indicated that people like to become high. In addition to feeling less stressed and afraid, chronic users reported feeling a variety of good emotions while high, including amazement, inspiration and thankfulness.

Interestingly, and against widespread perceptions, chronic users’ levels of paranoia did not rise when they got high. However, it was associated with decreased momentary conscientiousness, indicating reduced self-control and organization.

Although cannabis intoxication had short-lived effects on chronic users’ emotional states, there was little evidence of a hangover the next day. Additionally, frequent users reported greater negative emotions but also higher motivation compared to less frequent users.

While the study could not conclusively determine causality, it suggested a complex relationship between cannabis use and emotional states. The authors acknowledge limitations in participant selection, noting that the sample may not represent less frequent or novice users. Despite these limitations, the study provides valuable insights into the everyday experiences of habitual cannabis users, challenging misconceptions and paving the way for future research.

Other recent studies have similarly challenged misconceptions about cannabis, including its neurocognitive effects, which were found to be minimal among medical cannabis patients with chronic health conditions. Additionally, marijuana use was associated with a lower likelihood of cognitive decline and improved cognitive functioning in some studies.

Contrary to claims that marijuana causes mental illness, research has shown modest improvements in cognitive functioning and reduced medication usage among teens and young adults at risk of psychosis who use marijuana regularly. Studies have also debunked claims of marijuana causing IQ loss, attributing observed declines in IQ to shared familial factors rather than marijuana use itself.

Overall, while the long-term effects of cannabis use remain uncertain, recent research suggests that many fears surrounding marijuana may be exaggerated, and further investigation is warranted to better understand its impacts.

As more such studies are conducted and clarify what effects cannabis can or cannot have on its medical or recreational users, entities such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) that focus on the production of pharmaceutical-grade marijuana products could see interest in their products grow as the therapeutic effects of cannabis become more familiar to the public.

NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannaCon West Albuquerque to Unite the Southwest Cannabis Industry

Traders, cannabis stakeholders, license holders, physicians, patients, regulatory authorities, entrepreneurs, capital investors, public officials, and enthusiasts, are invited to attend the CannaCon West Albuquerque at the Albuquerque Convention Center on May 17-18, 2024. The event focuses on bringing together all participants in the cannabis industry for two days of intense exploration, interaction, learning, and collaboration.

As Albuquerque is witnessing an evolving cannabis industry, this event provides a phenomenal platform for cannabis veterans and newcomers to build a solid new industry. The CannaCon West Albuquerque is engaged in boosting the West’s cannabis industry. The Albuquerque network consists of like-minded cannabis businesses that stay connected and support each other, paving the way for growth and higher returns.

Influential industry leaders and decision-makers will talk about the latest issues and regulations, trends, innovations, and strategies. They will also answer queries from attendees during discussions and interactive sessions. The CannaCon expo offers a global networking frontier where eminent canna traders and investors visit to discover new and fresh talent and ideas. This event opens up avenues for trade and opportunities for all segments of cannabis industries in the region.

CannaCon is a one-stop shop offering a gamut of services to attendees ranging from retail displays, cultivation supplies, showcasing industry innovations, world-class genetics, business and legal advice, science and technology, finance, marketing, and so on. New and seasoned entrepreneurs and industry leaders will showcase their offerings to ensure visibility among industry experts and professionals.

Attendees can meet and connect with decision-makers, veterans, and investors and grow their network at CannaCon in a fun and conducive environment.

Bookings for exhibitors and speaker sessions are available.

To learn more, please visit https://cnw.fm/nnKt1

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance

  • Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares
  • The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses
  • Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per share, respectively, with the whole undertaking yielding approximately $4.7 million, prior to deducting estimated offering expenses (https://cnw.fm/YbeyA).

Proceeds from this offering will fund the 2024 GLP-1 research program and go into Lexaria’s working capital. Chris Bunka, the company’s CEO, noted that the funds will further extend its operational runway deep into 2025, an integral milestone given its project pipeline, specifically its focus on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year.

“These additional cash proceeds of $4.7 million further extend Lexaria’s operational runway deep into 2025 and allow us to execute our 2024 plans at an aggressive pace,” noted Mr. Bunka.

This announcement closely follows Lexaria’s recent milestone of three additional patents to its portfolio. In April 2024, the company received two newly granted patents in the U.S. and one in Japan. The first two patents fell under the company’s patent family #24: Compositions and Methods for Treating Epilepsy, while the third fell under patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. While the company maintains its standing on the value of its intellectual property and continues to pursue that, its focus for 2024 has been specifically focused on GLP-1 studies.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations. We are not at this time planning additional 2024 research in antiviral nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka (https://cnw.fm/w21gI).

The $4.7 million will be integral in realizing this objective for the company, even as it pushes for patent applications. With this, its management maintains that its hard work will prove itself in 2024, ultimately creating additional shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — US Cannabis Companies Could Soon Access Bankruptcy Protection

U.S. cannabis businesses undergoing distress often face hurdles in seeking bankruptcy protection, a common challenge in an industry prone to business downturns. However, there’s a glimmer of hope on the horizon with potential federal rescheduling of cannabis and shifting perspectives evident in recent bankruptcy cases.

Duane Morris Law firm associate, Ryan Spengler, expressed cautious optimism, noting that advancements in court rulings coupled with potential rescheduling may pave the way for new bankruptcy avenues for U.S. marijuana businesses. He stated that even before federal rescheduling, if bankruptcy courts begin to show leniency towards marijuana-related companies, it could signal a positive trend for the industry.

Meanwhile, distressed marijuana enterprises are exploring out-of-court restructuring and state court receiverships as alternatives to filing for federal bankruptcy. Some are even turning to Canadian insolvency rules, where applicable.

Federal bankruptcy laws in the United States mandate that bankruptcy plans must be proposed in good faith and in compliance with all applicable regulations. Since cannabis remains illegal under federal law, even state-regulated cannabis companies are excluded from federal bankruptcy protections.

Although rescheduling marijuana might seem like a solution, Spengler points out that it wouldn’t address the federal barrier to bankruptcy. He explains that regardless of whether marijuana is classified as Schedule I or III, bankruptcy courts would still view it as a federal violation.

New court rulings, nevertheless, provide some hope. A possible change in perspective is indicated by the fact that certain courts have started to permit the division of assets connected to cannabis for the advantage of debtors and creditors.

For instance, a 2023 ruling by a California bankruptcy court set a precedent by allowing the sale of stock in a Canadian marijuana company as part of a bankruptcy plan. Similarly, another case in 2023 saw approval from a bankruptcy court indicating the potential for more innovative approaches in marijuana bankruptcy cases.

Rescheduling marijuana could present fresh prospects for bankrupt cannabis companies, according to Kevin McLaughlin, a partner at Centri Business Consulting. He anticipates that eliminating 280E taxation, which is associated with Schedule III classification, could make cannabis businesses more attractive for restructuring. Despite the limitations in bankruptcy options, McLaughlin notes that cannabis companies still have alternatives such as out-of-court restructuring and receivership.

In the meantime, as regulated cannabis companies await changes in bankruptcy laws, income derived from the marijuana industry also poses challenges in personal bankruptcy cases.

Recent court decisions indicate a gradual shift away from a strict stance against marijuana-involved debtors seeking bankruptcy relief. This shift offers a glimmer of hope for individuals working in the industry who may seek bankruptcy protection in the future.

Any positive reforms to the existing federal marijuana policies are likely to be a welcome development to industry actors such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) given how much the current prohibitionist environment has hamstrung their operations and growth.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg semaglutide dose formulations: A positive control Rybelsus(R) swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. According to the announcement, the second DehydraTECH study arm will use a Rybelsus(R) composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database (“FDA IID”), delivered within swallowed capsules. The dosing interval is currently anticipated to complete during mid-June, after the necessary wash-out period for the participants from the first study arm.

To view the full press release, visit https://cnw.fm/Zftos

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria’s patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Zoned Properties Inc. (ZDPY) Emerges as a Crucial Partner for the Cannabis Industry; Announced Planned $1 Million Share Buyback

  • Cannabis retail dispensaries in Arizona have grown to upwards of 168 locations as of January 2024
  • Nonetheless, only 1% of Arizona’s commercial properties are eligible for use by the cannabis industry
  • Zoned Properties has been a key partner for the industry in helping cannabis companies establish a physical retail presence
  • The company has recently announced the approval of a $1 million share buyback plan

The legalized sale of recreational cannabis in Arizona has grown from strength to strength. Possession and cultivation of cannabis across the state became legal on November 30, 2020, with the state-licensed sale of recreational cannabis commencing on January 22, 2021 making Arizona the quickest state in U.S. history to begin retail sales post recreational legalization. Cannabis sales in the state drove over $1.4 billion in revenues in 2023, with the number of dispensaries swelling to 292 as of January 2024 (https://cnw.fm/UyEP2). Nevertheless, further expansion for the industry is easier said than done; at present, only 1 percent of Arizona’s commercial real estate properties are applicable to cannabis operators, imposing a further constraint on the growth and development of the state’s cannabis retail market.

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States, has been amongst the early leaders in facilitating the transition of the cannabis industry towards the physical retail space. The company maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois; with each of its leased properties occupied by commercial cannabis-linked businesses, the company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years.

Zoned Properties has been amongst the leaders in identifying and procuring registered cannabis facilities, which can subsequently be sub-leased to the cannabis industry. Bryan McLaren, Chairman and CEO of Zoned Properties elaborated on the company’s methodology during a recent interview with the Bell2Bell podcast (https://cnw.fm/DSBPc).

“Our company and our team go into these state marketplaces and we identify, qualify and get these properties approved that can be utilized as regulated cannabis facilities. In the best-case scenario, what we’re doing is securing a piece of retail real estate – an old bank, an old restaurant, an old quick service retail location – getting that property approved to be used as a cannabis site called a retail dispensary and leasing that property out to a third-party tenant with a cannabis license in that location under a long-term lease agreement.”

Zoned Properties’ unique business model has translated into a faster rate of operational growth, with the company recently revealing that it had acquired a further two sites for use as potential dispensary locations. Separately, the company has looked to combine its ambitious focus on growth with a desire to maximise total shareholder returns; Zoned Properties recently announced that its Board of Directors has approved a stock repurchase program, pursuant to which the company was authorized to purchase up to $1 million of its common stock over an unlimited time period (https://cnw.fm/wivYQ).

“As our business continues to outperform in a challenging overall operating environment, we are thrilled to announce this share repurchase program. The approval of this program demonstrates the management teams and board’s confidence in our prospects for the future, ongoing operational strength, and sound capital structure,” stated McLaren. “As we scale the investment portfolio, we are keeping conservative in our capital allocation strategy while also acknowledging the significant valuation gap between our public valuation and tangible book value. Due to this, it is crucial for us to be adaptable and make sure we are doing everything possible to increase shareholder value. As always, we remain committed in our strategic focus, and look forward to updating shareholders on our progress,” he continued.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://cnw.fm/ZDPY

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Signature Collection Can Begin After North Dakota Cannabis Legalization Ballot Initiative Gains Official Approval

Michael Howe, North Dakota’s secretary of state, recently gave the green light for the circulation of a petition aiming to legalize marijuana. If approved, the measure would allow adults aged 21 and older to grow, process, use and sell cannabis. Additionally, it would establish a regulatory body to oversee marijuana-related entities within the state.

The proposal also includes specific regulations concerning processing and production, as well as restrictions on usage, such as in vehicles and public spaces, and provisions for home cultivation.

To qualify for inclusion on the ballot, supporters of the petition must gather a minimum of 15,582 signatures by April 25 next year. Should they meet this deadline by July 8 this year, the legislation will be put to a vote in November’s general election. However, if the required signatures are collected after this date but before next year’s deadline, the legislation will be deferred to the next statewide election, anticipated to occur in 2026.

An advertisement posted on Indeed reveals that advocates of the proposal are seeking North Dakotans to assist in petition circulation across various cities, including Dickinson, Bismarck, Devils Lake, Grand Forks, Fargo, Jamestown, Williston and Minot.

Spearheading the initiative is Steve Bakken, a former mayor of Bismarck and current Burleigh County commissioner. Bakken underlined the need for more efficient use of resources, particularly in the fight against illegal drugs and substances such as fentanyl. He also emphasized the group’s goal of averting the possible adoption of a badly written initiative.

In previous years, voters in the state have rejected similar measures to legalize cannabis, with 55% opposing the proposal in 2022 and an even larger margin against it in 2018. Despite these setbacks, in 2021, the state’s House passed legislation aimed at legalizing and taxing recreational cannabis. However, these efforts were thwarted by the GOP-led senate.

Voters approved medical cannabis in 2016, leading to the establishment of a state-run program that currently serves about 10,000 patients. Additionally, the state’s Pardon Advisory Board introduced a new procedure to streamline pardons for minor cannabis offenses in 2019, resulting in 100 pardons by Governor Doug Burgum.

Currently, 24 states have legalized recreational cannabis, with Ohio being the most recent to do so through a ballot initiative last year. Additionally, similar initiatives are being carried out in other states. Florida is scheduled to vote on a ballot measure in November, and there are active signature-collection campaigns in states including South Dakota, Nebraska and Arkansas.

The opportunity for voters in North Dakota to end marijuana prohibition will likely be watched by industry companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) because the enactment of a law creating a marijuana market would give residents the choice to consume marijuana for recreational purposes much like it is happening in other states around the country.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Golden Triangle Ventures Inc. (GTVH) New Acquisition Takes Lavish Division One Step Closer to Development of Premier Music, Art Destination

  • More than half of Americans have attended a music festival, indicating lucrative potential for music and art destinations
  • GTVH recently closed on the acquisition of ABI Create, a premier event-management and production company
  • With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever

With Coachella still fresh in music lovers’ memories, it’s only natural to look at what other amazing music festivals might be looming in the future. Destino Ranch comes to mind. A new project focused on becoming an international destination where nature and technology combine to create unforgettable experiences such as outstanding music festivals, Destino Ranch is being developed by Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment.

Officially called the Coachella Valley Music and Arts Festival, Coachella is held over two weekends at the Empire Polo Club in Indio, California, in the Coachella Valley in the Colorado Desert. The event traditionally features an array of musical artists from different music genres, including rock, pop, indie, hip hop and more; the festival also includes art installations and sculptures.

This year, Coachella saw record attendance, with organizers reporting an estimated 300,000 people flocking to Indio (https://cnw.fm/kBJIS). In addition, Coachella’s revenue is impressive, bringing in $115 million collectively from ticket, food and beverage sales and generating around $700 million for the local economy in Indio and surrounding cities each year (https://cnw.fm/t2t9R).

There’s definitely an eager audience for events such as music and art festivals. In fact, a Marketing Chart study reported that “overall, roughly one-third (34%) of American adults surveyed report having been to more than one music festival, while an additional fifth (20%) say they’ve been once. As such, some 54% of U.S. adults have been to at least one music festival” (https://cnw.fm/gphBd).

Clearly, Golden Triangle Ventures and Lavish Entertainment are on to something. Most recently the company took a significant step forward in the development of Destino Ranch with the acquisition of ABI Create, a premier event-management and production company (https://cnw.fm/QmBvF). Founded by Marco Antonio Moreno, who was recently named president and COO of Lavish Entertainment, ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States, including the NFL Super Bowl, San Diego and New York Comic Con events, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man and more.

The completed acquisition will transition ABI Create into a wholly owned subsidiary of Lavish Entertainment, strengthening Lavish’s position in the entertainment industry through ABI’s well-known reputation and proven track record of executing high-level projects. Headquartered in Las Vegas, ABI’s comprehensive suite of services includes event organization, management, production, logistics, site planning, permitting, construction, contracting, custom design and fabrication.

With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever. With access to nearly 22,000 visitors traveling through the area every day, the ranch could quickly become a modern art and music festival mecca. In fact, current plans call for the destination location to include an immersive, world-class art installation gallery with rotating exhibits as well as a large-scale music venue with state-of-the-art staging and production, all carefully designed to complement the beautiful natural attributes of the surrounding Mojave Desert.

“This acquisition of ABI Create sets the stage for us to begin showcasing all other synergistic divisions within Lavish that will support all resources, relationships and partnerships within the ABI portfolio of offerings,” said Steffan Dalsgaard, CEO of Golden Triangle Ventures. “Our goal is to develop ABI into a one-stop-shop, event-management business within Lavish that will hold a complete suite of event management and development services. This aims to complement all internal projects and productions and will potentially support outside business opportunities that can provide fundamental synergies to our ultimate plan of building a complete entertainment enterprise.”

Golden Triangle Ventures is a multifaceted consulting company that operates as a parent business pursuing ventures in the health, entertainment and technology sectors, as represented by the three-point golden triangle, along with other sectors that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://cnw.fm/GTVH

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

  • Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
  • Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
  • GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
  • The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.

According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://cnw.fm/5ROKd). Studies showed a massive spike in overall incidences of type 2 diabetes between 2002 and 2018, with one of the main cited risk factors being obesity. The CDC noted that of those diagnosed with the condition, 89.8% of them were overweight or obese, as defined by a body mass index (“BMI”) of 25 kg/m2 or higher. This was further compounded by physical inactivity, with 31.9% of those diagnosed reporting getting less than 10 minutes a week of moderate or vigorous activity (https://cnw.fm/onJuB).

In March, Lexaria announced details of its upcoming 12-week animal study WEIGHT-A24-1 that will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://cnw.fm/9yxZw). Results will guide additional human investigations.

The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and tolerable oral delivery option for diabetes treatment and weight loss management (https://cnw.fm/oDqd6).

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO.

“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” he added.

Previous Lexaria studies have demonstrated that DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms. Already, GLP-1R agonists have been shown to penetrate the brain and activate a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. With the upcoming studies, Lexaria looks to evidence that DehydraTECH processing of GLP-1 drugs can enable even faster penetration into brain tissue, ultimately improving overall efficiency in weight loss and blood sugar control. Its management is optimistic that it will replicate the success of previous studies and looks forward to kickstarting the undertaking.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — German Marijuana Imports Reached Record Levels in 2023

Germany saw a significant surge in its marijuana imports for scientific and medical purposes last year, reaching a record high, indicating a growing interest from international businesses eyeing opportunities in Europe’s largest federally regulated medical cannabis market. According to the latest data from the Federal Institute for Drugs & Medical Devices (BfArM), the country imported 36.4 tons (31,398 kilograms) of marijuana products last year. This marks a notable increase of 26.2% compared to the previous year’s import volume of 24,876 kilograms.

The trend of increasing imports has been consistent through the years. In 2022, the country saw imports of 27.4 tons (24,876 kilograms) of marijuana, reflecting a 19.8% increase from the previous year. The year 2021 saw imports of 22.9 tons (20,771 kilograms), representing a significant surge of 77% over the previous year.

In 2020, imports totaled 12.8 tons (11,746 kilograms), indicating a 46% increase from 2019, while in 2019, Germany imported 8.9 tons (8,057 kilograms) of marijuana, which was an 80% increase from the previous year’s imports. While some of these imports are re-exported to other European Union countries annually, experts suggest that the data underscores the rapid growth of the industry.

Only three businesses were authorized to grow medical cannabis in 2019; these companies were given strict output targets that would last for four years. Due to this restriction, cannabis had to be imported from overseas to meet demand. However, changes in marijuana law have the potential to reduce its dependence on imports in the future. The new law eliminates the quota system, allowing companies to apply for permits to grow medical cannabis through the agency.

Furthermore, the recent revision of the marijuana law, effective April 1, 2024, has reclassified the substance, removing it from the list of narcotics. This regulatory change simplifies the process for patients seeking medical marijuana because they will no longer be required to have a narcotic prescription form. Standard prescriptions will now suffice, likely stimulating demand in the market.

Despite the optimism for increased domestic cultivation, Germany is expected to continue relying on significant imports in the foreseeable future. German-based Demecan’s managing director, Von der Groeben, pointed out Article 21 of the UN Single Convention on Narcotic Drugs, which suggests that domestic demand must be met before imports can be halted. However, he acknowledges that achieving self-sufficiency in marijuana production may take several years.

Canada remained the primary supplier of marijuana to the German market last year, accounting for approximately 50% of imports. Portugal came in second, while the Netherlands was the third-largest supplier.

The further easing of marijuana laws in Germany could create additional opportunities that major players in the North American cannabis landscape, such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), may look to exploit as they expand their footprint in different legal markets.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN